$CALC Balance Sheet | Understand Stock

$CALC

$1.31 +$0.01 (0.77%) Close

$CALC Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current assets:
Cash and cash equivalents
Restricted Cash
Short-term investments
Prepaid clinical trial expenses
Other prepaid expenses and current assets
Assets held for sale
Total current assets
Property and equipment, net
Prepaid expenses and other non-current assets
Right-of-use asset, net
Other assets
Total assets

Liabilities and Stockholders' Equity (Deficit)
Current liabilities
Accounts payable
Accrued research and development
Operating lease liability, current
Accrued Transaction Costs
Accrued severance
Accrued payroll and other employee benefits
Accrued clinical trial costs
Accrued expenses
Other current liabilities
Current portion, promissory note
Total current liabilities

Deferred rent, long term portion
Operating lease liability, net of current portion
Warrant liability
Convertible promissory notes
Promissory note
Long-term liabilities
Promissory note
Warrant liability
Total liabilities
Convertible preferred stock
Series A Convertible Preferred Stock
Series B
Series C-1Convertible Preferred Stock
Series C-2 Convertible Preferred Stock
Series D Convertible Preferred Stock
Stockholders' equity (deficit)
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Common stock, $0.0001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 30,736,401 and 15,437,410, issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders' equity (deficit)
Total liabilities and stockholders' equity (deficit)

Comments